인간 마이크로바이옴 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Human Microbiome Market size is expected to reach USD 12.88 Billion in 2034 from USD 2.29 Billion (2025) growing at a CAGR of 21.16% during 2026-2034.

The global human microbiome market is experiencing rapid growth due to increasing research on the role of microorganisms in human health. The human microbiome is linked to various conditions, including gastrointestinal disorders, metabolic diseases, and immune system regulation. Growing awareness about the importance of gut health and the rising demand for probiotic and microbiome-based therapies are driving market expansion. Additionally, advancements in sequencing technologies are enabling deeper insights into microbial communities.

Key growth drivers include increasing investments in microbiome research and the expanding applications of microbiome-based products in healthcare and nutrition. Pharmaceutical and biotechnology companies are focusing on developing microbiome-targeted therapies for various diseases. The rising popularity of personalized medicine and preventive healthcare is also contributing to market growth. Furthermore, collaborations between research institutions and industry players are accelerating innovation in this field.

Looking ahead, the human microbiome market is expected to grow significantly with ongoing research and technological advancements. The development of targeted microbiome therapies and diagnostics will expand clinical applications. Emerging markets are likely to offer new opportunities due to increasing health awareness and improving healthcare infrastructure. Additionally, regulatory advancements and standardization will support the commercialization of microbiome-based products.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Site

• Digestive Tract
• Lung
• Reproductive Cavity
• Skin
• Other Sites

By Application

• Therapeutics
• Diagnostics

By Disease

• Infectious Disease
• Gastrointestinal Disease
• Endocrine And Metabolic Diseases
• Cancer
• Central Nervous System Disorder
• Other Diseases

By Product

• Drugs
• Supplements
• Diagnostic Tests
• Other Products

COMPANIES PROFILED

• Archer Daniels Midland Company, , Biohm Technologies, BioGaia, Biome Diagnostics, BiomeBank, Ferring, Intralytix, OptiBiotix, Pendulum Therapeutics, Prescient Metabiomics, Seres Therapeutics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN MICROBIOME MARKET: BY SITE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Site
• 4.2. Digestive Tract Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Reproductive Cavity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Skin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Sites Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN MICROBIOME MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN MICROBIOME MARKET: BY DISEASE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease
• 6.2. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gastrointestinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Endocrine And Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Central Nervous System Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN MICROBIOME MARKET: BY PRODUCT 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Product
• 7.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HUMAN MICROBIOME MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Site
  • 8.2.2 By Application
  • 8.2.3 By Disease
  • 8.2.4 By Product
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Site
  • 8.3.2 By Application
  • 8.3.3 By Disease
  • 8.3.4 By Product
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Site
  • 8.4.2 By Application
  • 8.4.3 By Disease
  • 8.4.4 By Product
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Site
  • 8.5.2 By Application
  • 8.5.3 By Disease
  • 8.5.4 By Product
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Site
  • 8.6.2 By Application
  • 8.6.3 By Disease
  • 8.6.4 By Product
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL HUMAN MICROBIOME INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Biohm Technologies
  • 10.2.2 BioGaia
  • 10.2.3 Biome Diagnostics
  • 10.2.4 BiomeBank
  • 10.2.5 Ferring
  • 10.2.6 Intralytix
  • 10.2.7 OptiBiotix
  • 10.2.8 Pendulum Therapeutics
  • 10.2.9 Prescient Metabiomics
  • 10.2.10 Seres Therapeutics